Citius Pharmaceuticals, Inc Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
$29.1 million in cash and cash equivalents as of March 31, 2023; $15 million registered direct offering in May 2023 extends runway through May 2024
Halo-Lido Phase 2b trial completed with topline. | June 14, 2023
/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.
/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development.
Citius Pharmaceuticals, Inc Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.